Yield10 Bioscience, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Oliver P. Peoples
- Full Time Employees
- 29
- Sector
- Basic Materials
- Industry
- Agricultural Inputs
- Address
- 19 Presidential Way Woburn MA United States of America 01801
- IPO Date
- Nov 10, 2006
- CIK
- 0001121702
- Website
- yield10bio.com
- Similar Companies
- Business
- Yield10 Bioscience, Inc., an agricultural biotechnology enterprise, historically concentrated on advancing methods to significantly boost crop productivity across North America. The company utilized its specialized trait discovery platform, known as the "Trait Factory," to engineer improved varieties of oilseed *Camelina sativa* for producing distinct seed products. These initiatives aimed to yield high-value offerings, including feedstock oils for renewable fuels, omega-3 oils for nutritional applications, and bioplastics. Over its operational history, Yield10 Bioscience engaged in various collaborations and licensing agreements within the agriculture and food sectors. The company, initially incorporated in 1992 as Metabolix, Inc., adopted the name Yield10 Bioscience, Inc. in January 2017. However, the company faced significant challenges, leading to its delisting from Nasdaq in May 2024, and subsequently filed for Chapter 11 bankruptcy in December 2024. As part of its restructuring process, substantially all of Yield10's core *Camelina* assets, including its omega-3 technology, were acquired by Nufarm in January 2025. Yield10 Bioscience, Inc. maintains its historical corporate base in Woburn, Massachusetts.
Yield10 Bioscience (NASDAQ:YTEN) Shares Pass Above 200 Day Moving Average – Here’s What Happened
Yield10 Bioscience Announces Adjournment of Special Meeting of Stockholders to Solicit Sufficient Votes in Favor of the Key Proposals
Yield10 Bioscience Announces Second Quarter 2024 Financial Results
Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets
Yield10 Bioscience Grants Nufarm a Commercial License to Omega-3 Assets for Producing Oil in Camelina, and Yield10 and Nufarm sign a Memorandum of Understanding for Sale of Assets
Rothamsted Research Grants Yield10 Bioscience an Exclusive, Global Commercial License to Advanced Technology for Producing Omega-3 Products in Camelina
Yield10 Bioscience Announces Addition of Camelina to INTERLINE® Herbicide Label
Yield10 Bioscience Announces First Quarter 2024 Financial Results
Yield10 Bioscience Announces Delisting from Nasdaq
2 Biotech Stocks to Watch Under $20
Yield10 Bioscience Announces 1-for-24 Reverse Stock Split
Yield10 Bioscience, Inc. (YTEN) Q4 2023 Earnings Call Transcript
Yield10 Bioscience Announces Fourth Quarter and Full Year 2023 Financial Results
Yield10 Bioscience to Announce Fourth Quarter and Full Year 2023 Financial Results and Host a Conference Call on Monday, April 1, 2024
Yield10 Bioscience Announces that the Plant Biosafety Office of the Canadian Food Inspection Agency has Cleared Genome-edited E3902 Camelina for Planting in Canada
Why Is Yield10 (YTEN) Stock Up 117% Today?
USDA-APHIS Determines that Yield10 Bioscience's Omega-3 Camelina Varieties May Be Planted and Bred in the United States
Yield10 Bioscience Reports that Proprietary Varieties of Winter Camelina Show Tolerance to Commonly Used Herbicides in First Field Tests
Yield10 Bioscience Grants Global License to VISION Bioenergy Oilseeds for Herbicide Tolerant Camelina Cultivated for the Production of Biofuel Feedstock
Yield10 Bioscience Provides an Update on its Omega-3 Camelina Program